
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Vesper Bio Reports Successful Phase I Study for Frontotemporal Dementia Treatment
Details : VES001 is a first-in-class oral, brain-penetrant, small molecule sortilin receptor inhibitor, is presently undergoing evaluation for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 04, 2024

Vesper Bio Completes Single Ascending Dose Stage for VES001 in Dementia Trial
Details : VES001, a oral small molecule sortilin receptor inhibitor, is presently completed Phase I evaluation for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2024

Details : VES001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VES001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : $0.8 million
Deal Type : Funding
Vesper Bio Awarded Grant to Assess Sortilin Inhibitors for Parkinson's
Details : The funding aims to support the clinical advancement of Vesper's lead product VES001, a sortilin inhibitor. Currently, it is being evaluated in the preclinical trial studies for Parkinson's disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : VES001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : $0.8 million
Deal Type : Funding

Details : VES001, a small molecule sortilin receptor inhibitor, is presently undergoing evaluation in ongoing Phase I clinical trials for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2023
